Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

首次发布于 2009 年 5 月 12 日

Genetic Counseling in Women at Risk for BRCA1 or BRCA2 Mutations

计划入组 1,109 人 · 首次发布于 2006 年 12 月 28 日

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

计划入组 10,000 人 · 首次发布于 2009 年 5 月 12 日

Correction of Q347X mutation(Beam Therapeutics)

KRAS mutation G12D-targeted ONCOlogues ( Oncogenuity)

Personalized Mutation-derived Tumor Vaccine(NovoCure)

Cogent Biosciences

United States

Nuvation Bio

United States

FONDS DE DOTATION HTC PROJECT

France

Veliparib Shows Promise in BRCA-Mutated Breast Cancer: Phase II Trial Results

Olaparib Provides Long-Term Survival Benefit in BRCA2-Mutated Ovarian Cancer

Risk-Reducing Surgeries Significantly Improve Survival in BRCA-Positive Breast Cancer Patients